PMID- 33871070
OWN - NLM
STAT- MEDLINE
DCOM- 20210924
LR  - 20210924
IS  - 1365-4632 (Electronic)
IS  - 0011-9059 (Linking)
VI  - 60
IP  - 10
DP  - 2021 Oct
TI  - Do we need skin toxicity? Association of immune checkpoint inhibitor and tyrosine 
      kinase inhibitor-related cutaneous adverse events with outcomes in metastatic 
      renal cell carcinoma.
PG  - 1242-1247
LID - 10.1111/ijd.15583 [doi]
AB  - INTRODUCTION: Skin toxicity is a common, expected side effect of tyrosine kinase 
      inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) used for metastatic 
      renal cell carcinoma (mRCC). We evaluated the association between skin toxicity 
      and clinical efficacy outcomes of these agents in mRCC patients. METHODS AND 
      MATERIALS: Data were obtained from patients with mRCC treated with TKIs and/or 
      ICIs from 2016-2019 at a referral hospital in Mexico City. Clinical outcomes were 
      compared among patients who developed treatment-related cutaneous adverse events 
      (AEs) and those without skin toxicity. RESULTS: Thirty-five patients with mRCC 
      were identified who were treated with sunitinib (51.4%), nivolumab plus 
      cabozantinib (28.6%), nivolumab monotherapy (17.1%), or ipilimumab plus nivolumab 
      plus cabozantinib (2.9%). Any grade skin toxicity was seen in 65.7% of patients. 
      With a median follow-up of 14 months, radiological responses were as follows: 
      48.6% stable disease, 25.7% partial response, and 2.8% complete response. 
      Compared to subjects without skin toxicity, patients who developed cutaneous AEs 
      had higher disease control rate 91.3% vs. 50.0% (P = 0.019) and superior 12-month 
      overall survival rate 91% vs. 67% (P = 0.01), respectively. There was a trend 
      toward improved median progression-free survival (16 months vs. 5 months, 
      P = 0.13). Grade 1-2 cutaneous toxicity was found to be predictive for disease 
      control, with HR 2.72 (95% CI 1.1-6.71, P = 0.030), and all grade cutaneous 
      toxicity was prognostic of overall survival, with HR 0.18 (95% CI 0.04-0.91, 
      P = 0.039). CONCLUSION: Cutaneous AEs are associated with improved overall 
      survival and response in patients with mRCC treated with immunotherapy and/or 
      TKIs.
CI  - (c) 2021 the International Society of Dermatology.
FAU - Corona-Rodarte, Eduardo
AU  - Corona-Rodarte E
AD  - Department of Internal Medicine, Instituto Nacional de Ciencias Medicas y 
      Nutricion Salvador Zubiran, Mexico City, Mexico.
FAU - Olivas-Martinez, Antonio
AU  - Olivas-Martinez A
AD  - Department of Internal Medicine, Instituto Nacional de Ciencias Medicas y 
      Nutricion Salvador Zubiran, Mexico City, Mexico.
AD  - Department of Biostatistics, University of Washington, Seattle, WA, USA.
FAU - Remolina-Bonilla, Yuly A
AU  - Remolina-Bonilla YA
AD  - Department of Hematology and Oncology, Instituto Nacional de Ciencias Medicas y 
      Nutricion Salvador Zubiran, Mexico City, Mexico.
FAU - Dominguez-Cherit, Judith G
AU  - Dominguez-Cherit JG
AD  - Department of Dermatology, Instituto Nacional de Ciencias Medicas y Nutricion 
      Salvador Zubiran, Mexico City, Mexico.
FAU - Lam, Elaine T
AU  - Lam ET
AD  - Division of Medical Oncology, Department of Medicine, University of Colorado 
      Anschutz Medical Campus, Aurora, CO, USA.
FAU - Bourlon, Maria T
AU  - Bourlon MT
AD  - Department of Hematology and Oncology, Instituto Nacional de Ciencias Medicas y 
      Nutricion Salvador Zubiran, Mexico City, Mexico.
LA  - eng
PT  - Journal Article
DEP - 20210419
PL  - England
TA  - Int J Dermatol
JT  - International journal of dermatology
JID - 0243704
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - 0 (Protein Kinase Inhibitors)
RN  - V99T50803M (Sunitinib)
SB  - IM
MH  - *Carcinoma, Renal Cell/drug therapy
MH  - Humans
MH  - Immune Checkpoint Inhibitors
MH  - *Kidney Neoplasms/drug therapy
MH  - Protein Kinase Inhibitors/adverse effects
MH  - Retrospective Studies
MH  - Sunitinib/therapeutic use
EDAT- 2021/04/20 06:00
MHDA- 2021/09/25 06:00
CRDT- 2021/04/19 08:54
PHST- 2021/01/25 00:00 [revised]
PHST- 2020/07/03 00:00 [received]
PHST- 2021/04/20 06:00 [pubmed]
PHST- 2021/09/25 06:00 [medline]
PHST- 2021/04/19 08:54 [entrez]
AID - 10.1111/ijd.15583 [doi]
PST - ppublish
SO  - Int J Dermatol. 2021 Oct;60(10):1242-1247. doi: 10.1111/ijd.15583. Epub 2021 Apr 
      19.